HighTower Advisors’s Caribou Biosciences CRBU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.8K Buy
17,934
+1,000
+6% +$1.56K ﹤0.01% 3789
2026
Q2
$29.8K Hold
16,934
– – ﹤0.01% 3754
2026
Q1
$32.2K Hold
16,934
– – ﹤0.01% 3739
2025
Q4
$26.9K Hold
16,934
– – ﹤0.01% 3602
2025
Q3
$39.5K Sell
16,934
-200
-1% -$378 ﹤0.01% 3625
2025
Q2
$21.6K Buy
17,134
+3,917
+30% +$3.85K ﹤0.01% 3612
2025
Q1
$12.1K Buy
13,217
+296
+2% +$385 ﹤0.01% 3550
2024
Q4
$20.5K Buy
+12,921
New +$26K ﹤0.01% 3541

Other funds holding CRBU

HighTower Advisors's CRBU Position: Q3 2026 in Review

HighTower Advisors increased its Caribou Biosciences (CRBU) stake by 5.9% in Q3 2026, buying an estimated $1.56K and bringing the position to 17,934 shares worth $22.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3789.

HighTower Advisors first reported a position in CRBU in Q4 2024 and has held it in 8 quarters since. The position peaked at $39.5K in Q3 2025. 113 funds tracked by Wall St. Rank hold CRBU as of Q3 2026.

  • HighTower Advisors held 17,934 shares of Caribou Biosciences worth $22.8K as of Q3 2026.
  • HighTower Advisors bought 1,000 Caribou Biosciences shares in Q3 2026, an estimated $1.56K.
  • Caribou Biosciences made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3789 holding.
  • HighTower Advisors first reported a position in Caribou Biosciences in Q4 2024 and has held it in 8 quarters since.
  • HighTower Advisors's Caribou Biosciences position peaked at $39.5K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.